NASDAQ:SMMT - SUMMIT THERAPEU/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SUMMIT THERAPEU/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.47 -0.06 (-3.92 %) (As of 01/29/2020 01:07 AM ET) Add Compare Today's Range$1.46Now: $1.47▼$1.5350-Day Range$1.42MA: $1.51▼$1.6852-Week Range$1.13Now: $1.47▼$2.46Volume18,908 shsAverage Volume35,056 shsMarket Capitalization$47.19 millionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMMT Previous Symbol CUSIPN/A CIK1599298 Webhttp://www.summitplc.com/ Phone44-12-3544-3939Debt Debt-to-Equity Ratio0.02 Current Ratio3.26 Quick Ratio3.26Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$56.50 million Price / Sales0.84 Cash Flow$1.05 per share Price / Cash Flow1.40 Book Value$4.08 per share Price / Book0.36Profitability EPS (Most Recent Fiscal Year)$0.84 Net Income$9.99 million Net Margins-2,107.69% Return on Equity-59.95% Return on Assets-42.26%Miscellaneous Employees61 Outstanding Shares32,100,000Market Cap$47.19 million Next Earnings Date3/25/2020 (Estimated) OptionableOptionable Receive SMMT News and Ratings via Email Sign-up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SMMT Rates by TradingView SUMMIT THERAPEU/S (NASDAQ:SMMT) Frequently Asked Questions What is SUMMIT THERAPEU/S's stock symbol? SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT." How were SUMMIT THERAPEU/S's earnings last quarter? SUMMIT THERAPEU/S (NASDAQ:SMMT) issued its earnings results on Tuesday, December, 17th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $4.07 million. SUMMIT THERAPEU/S had a negative net margin of 2,107.69% and a negative return on equity of 59.95%. View SUMMIT THERAPEU/S's Earnings History. When is SUMMIT THERAPEU/S's next earnings date? SUMMIT THERAPEU/S is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for SUMMIT THERAPEU/S. What price target have analysts set for SMMT? 2 brokerages have issued 12-month target prices for SUMMIT THERAPEU/S's shares. Their forecasts range from $2.00 to $2.00. On average, they expect SUMMIT THERAPEU/S's stock price to reach $2.00 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S. What is the consensus analysts' recommendation for SUMMIT THERAPEU/S? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S. Has SUMMIT THERAPEU/S been receiving favorable news coverage? News coverage about SMMT stock has been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. SUMMIT THERAPEU/S earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for SUMMIT THERAPEU/S. Who are some of SUMMIT THERAPEU/S's key competitors? Some companies that are related to SUMMIT THERAPEU/S include Aptinyx (APTX), Bicycle Therapeutics (BCYC), Evelo Biosciences (EVLO), Nature's Sunshine Products (NATR), Spero Therapeutics (SPRO), Syndax Pharmaceuticals (SNDX), Arbutus Biopharma (ABUS), IDEAYA Biosciences (IDYA), Monopar Therapeutics (MNPR), Obseva (OBSV), Fortress Biotech (FBIO), Akorn (AKRX), Tyme Technologies (TYME), Ovid Therapeutics (OVID) and TAIWAN LIPOSOME/S (TLC). What other stocks do shareholders of SUMMIT THERAPEU/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other SUMMIT THERAPEU/S investors own include Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE), Catabasis Pharmaceuticals (CATB), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER) and Martin Midstream Partners (MMLP). Who are SUMMIT THERAPEU/S's key executives? SUMMIT THERAPEU/S's management team includes the folowing people: Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)Ms. Melissa Strange FCCA, VP of Fin. & Company Sec. (Age 39)Ms. Michelle Avery, Director of Investor Relations When did SUMMIT THERAPEU/S IPO? (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. How do I buy shares of SUMMIT THERAPEU/S? Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is SUMMIT THERAPEU/S's stock price today? One share of SMMT stock can currently be purchased for approximately $1.47. How big of a company is SUMMIT THERAPEU/S? SUMMIT THERAPEU/S has a market capitalization of $47.19 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe.View Additional Information About SUMMIT THERAPEU/S. What is SUMMIT THERAPEU/S's official website? The official website for SUMMIT THERAPEU/S is http://www.summitplc.com/. How can I contact SUMMIT THERAPEU/S? SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected] MarketBeat Community Rating for SUMMIT THERAPEU/S (NASDAQ SMMT)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 263 (Vote Outperform)Underperform Votes: 302 (Vote Underperform)Total Votes: 565MarketBeat's community ratings are surveys of what our community members think about SUMMIT THERAPEU/S and other stocks. Vote "Outperform" if you believe SMMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SMMT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: How does quantitative easing work?
